The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Hermann EinseleVideo series
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myeloma?
Einsele begins by explaining why bridging therapy is important in patients with multiple myeloma with a high tumor load. This is followed by a discussion on what should be considered when choosing a bridging therapy regimen, such as the incidence of cytopenias and infection risk.
More from this series:
